Dynamic microsimulation models for health outcomes: A review

Medical Decision Making

Volumn 31, Issue 1, 2011, Pages 10-18

  Rutter, Carolyn M ^a,b   Zaslavsky, Alan M ^c   Feuer, Eric J ^d  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Decision analytic models; Discrete event simulation

Indexed keywords

COMPARATIVE EFFECTIVENESS; COMPUTER SIMULATION; DECISION MAKING; HEALTH CARE POLICY; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; REVIEW;

COMPARATIVE EFFECTIVENESS RESEARCH; COMPUTER SIMULATION; DECISION MAKING; HEALTH POLICY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 79953865280     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10369005     Document Type: Review

References (110)

1. Orcutt GH. A new type of socio-economic system. Review of Economics and Statistics. 1957;80:1081-100.
2. National Research Council (US). Panel to Evaluate Microsimulation Models for Social Welfare Programs. Improving information for social policy decisions: the uses of microsimulation modeling. In: Citro CF, Hanushek EA, eds. Review and Recommendations. Vol 1I. Washington, DC: National Academy Press; 1991.
3. Lemp JD, McWethy LB, Kockelman KM. From aggregate methods to microsimulation-assessing benefits 80 of microscopic activity-based models of travel demand. Transportation Research Record. 2007;1994:80-8.
4. Hoogendoorn SP, Bovy PHL. State-of-the-art of vehicular traffic flow modelling. Proc Inst Mech Eng. 2001;215(14):283-303. (Pubitemid 34459578)
5. Hollocks BW. Forty years of discrete event simulation-a personal reflection. Journal of the Operational Research Society. 2006;57:1383-99. (Pubitemid 44771076)
6. Cassels S, Clark SJ, Morris M. Mathematical models for HIV transmission dynamics: tools for social and behavioral science research. J Acquir Immune Defic Syndr. 2008;47(suppl 1):S34-9. (Pubitemid 351323599)
7. Castiglione F, Pappalardo F, Bernaschi M, Motta S. Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics. 2007;23(24):3350-5. (Pubitemid 350238888)
8. Ackerman E, Longini IM Jr, Seaholm SK, Hedin AS. Simulation of mechanisms of viral interference in influenza. Int J Epidemiol. 1990;19(2):444-54. (Pubitemid 20197590)
9. Ackerman E, Zhuo Z, Altmann M, et al. Simulation of stochastic micropopulation models-I. The SUMMERS simulation shell. Comput Biol Med. 1993;23(3):177-98. (Pubitemid 23169580)
10. Peterson D, Gatewood L, Zhuo Z, Yang JJ, Seaholm S, Ackerman E. Simulation of stochastic micropopulation models-II. VESPERS: epidemiological model implementations for spread of viral infections. Comput Biol Med. 1993;23(3):199-213. (Pubitemid 23169581)
11. Longini IM Jr, Halloran ME, Nizam A, et al. Containing a large bioterrorist smallpox attack: a computer simulation approach. Int J Infect Dis. 2007;11(2):98-108. (Pubitemid 46283523)
12. Plaisier AP, van Oortmarssen GJ, Habbema JD, Remme J, Alley ES. ONCHOSIM: a model and computer simulation program for the transmission and control of onchocerciasis. Comput Methods Programs Biomed. 1990;31(1):43-56. (Pubitemid 20035444)
13. Habbema JD, Alley ES, Plaisier AP, van Oortmarssen GJ, Remme JH. Epidemiological modelling for onchocerciasis control. Parasitol Today. 1992;8(3):99-103.
14. Habbema JD, De Vlas SJ, Plaisier AP, Van Oortmarssen GJ. The microsimulation approach to epidemiologic modeling of helminthic infections, with special reference to schistosomiasis. Am J Trop Med Hyg. 1996;55(5 suppl):165-9. (Pubitemid 26391393)
15. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191-215. (Pubitemid 351271379)
16. Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci U S A. 14 2002;99(suppl 3):7280-7. (Pubitemid 34522724)
17. Tesfatsion L, Judd KL. Handbook of Computational Economics. Vol 2. North-Holland (Amsterdam): Elsevier; 2006.
18. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1985;20(1): 79-93. (Pubitemid 16217562)
19. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. Model building on the basis of Dutch cervical cancer screening data. Maturitas. 1985;7(1):11-20. (Pubitemid 15001267)
20. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer. 1990;66(7):1601-12. (Pubitemid 20355432)
21. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32(1):13-33. (Pubitemid 29102594)
22. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-78. (Pubitemid 36833878)
23. Wolfson MC. POHEM-a framework for understanding and modelling the health of human populations. World Health Stat Q. 1994;47(3-4):157-76.
24. Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK. Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions. Eur J Cancer. 2001;37(14):1797-804. (Pubitemid 32817055)
25. Microsimulation. 2009. Available from: http://www.statcan.ca/english/ spsd/. Accessed June 12, 2009.
26. Brown JB, Palmer AJ, Bisgaard P. The Mount Hood Challenge: cross-testing two diabetes simulation models. Diabetes Care. 2000;50(suppl 3):S57-64.
27. Group TMHM. Computer modeling of diabetes and its complication: a report on the 4th Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638-46.
28. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation. 1996;94(5):957-65. (Pubitemid 26292847)
29. Smolen HJ, Cohen DJ, Samsa GP, et al. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis. Value Health. 2007;10(6):489-97. (Pubitemid 350017483)
30. Matchar DB, Samsa GP, Matthews JR, et al. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med. 1997;127(8 pt 2):704-11. (Pubitemid 27446552)
31. Puvimanasinghe JP, Takkenberg JJ, Edwards MB, et al. Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation. Heart. 2004; 90(10):1172-8. (Pubitemid 39279905)
32. Ouwens JP, Groen H, TenVergert EM, Koeter GH, de Boer WJ, van der Bij W. Simulated waiting list prioritization for equitable allocation of donor lungs. J Heart Lung Transplant. 2002;21(7): 797-803. (Pubitemid 34718185)
33. Groen H, van der Bij W, Koeter GH, TenVergert EM. Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am J Transplant. 2004;4(7):1155-62. (Pubitemid 38868608)
34. Vanness DJ, Tosteson AN, Gabriel SE, Melton LJ 3rd. The need for microsimulation to evaluate osteoporosis interventions. Osteoporos Int. 2005;16(4):353-8. (Pubitemid 40487392)
35. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166(11):1209-17. (Pubitemid 43877630)
36. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298(6):629-37. (Pubitemid 47236414)
37. Alagoz O, Bryce CL, Shechter S, et al. Incorporating biological natural history in simulation models: empirical estimates of the progression of end-stage liver disease. Med Decis Making. 2005; 25(6):620-32. (Pubitemid 41667131)
38. Karnon J, Goyder E, Tappenden P, et al. A review and critique of modelling in prioritising and designing screening programmes. Health Technol Assess. 2007;11(52):iii-iv, ix-xi, 1-145.
39. National Cancer Institute. Cancer Intervention and Surveillance Modeling Network (CISNET). 2008. Available from: http://cisnet.cancer.gov/Accessed on 9 April 2010.
40. Models of Infectious Disease Agent Study, MIDAS. 2009. Available from: http://www.nigms.nih.gov/Initiatives/MIDAS/Accessed June 12, 2009.
41. COMnet. 2009; http://obesitymodeling.net/beta/Accessed June 12, 2009.
42. TreeAge [computer program]. Williamstown (MA): TreeAge Software, Inc.; 2008.
43. Kelton DW, Sadowski RP, Sturrock DT. Simulation with Arena. 4th ed. Boston: McGraw-Hill; 2007.
44. McEwan P, Williams JE, Griffiths JD, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;21(4):318-23. (Pubitemid 38519665)
45. Bellsey J, Sheldon AM. Healthcare Applications of Decision Analytic Modeling. Health Economics in Prevention and Care. 2000;1:37-43.
46. Hernandez R, Vale L. The value of myocardial perfusion scintigraphy in the diagnosis and management of angina and myocardial infarction: a probabilistic economic analysis. Med Decis Making. 2007;27(6):772-88. (Pubitemid 350147815)
47. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129-37. (Pubitemid 41278947)
48. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-90. (Pubitemid 34814727)
49. van der Akker-van Marle ME, van Ballegooijen M, van Ootmarssen GJ, Boer R, Habbema JDF. Cost-effectivness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst. 2002;94:193-204. (Pubitemid 34162753)
50. Vogelaar I, Van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Cancer. 2006;107:1623-33.
51. National Cancer Institute. Colorectal Cancer Mortality Projections. Dec 2007. Available from: http://cisnet.cancer.gov/projections/colorectal/Accessed 9 April 2010.
52. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659-69.
53. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-7. (Pubitemid 26400242)
54. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal- occult-blood test. Lancet. 1996;348(9040):1467-71. (Pubitemid 26400241)
55. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317: 559-65. (Pubitemid 28395924)
56. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326(10):653-7.
57. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst. 1990;82(22):1769-72.
58. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112(1):24-8. (Pubitemid 27008981)
59. Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359(12):1207-17.
60. HHS.gov. Centers for Medicare & Medicaid Services (CMS). 2008. Available from: http://www.cms.hhs.gov/mcd/viewmcac.asp?from2=viewmcac. asp&where=index&mid=45& Strike 2008. Accessed 9 April 2010.
61. Lee RC, Donaldson C, Cook LS. The need for evolution in healthcare decision modeling. Med Care. 2003;41(9):1024-33.
62. Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res. 2004;13(6):421-42. (Pubitemid 39562701)
63. Luebeck EG, Moolgavkar SH, Liu AY, Boynton A, Ulrich CM. Does folic acid supplementation prevent or promote colorectal cancer? Results from model-based predictions. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1360-7.
64. Cox DR, Miller HD. The Theory of Stochastic Processes. London: Chapman and Hall Ltd.; 1965.
65. Beck J, Pauker S. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58. (Pubitemid 14196965)
66. National Cancer Institute. Surveillance, Epidemiology and End Results-SEER 9 Regs Public Use. 2004. Available from: Strike 2004. Accessed 9 April 2010.
67. Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr. 2006(36):15-9.
68. National Center for Health Statistics. US Life Tables. 2000. Available from: www.cdc.gov/nchs/products/life-tables.htm, Strike 1960-2000. Accessed 9 April 2010.
69. Bickel PJ, Doksum KA. Mathematical Statistics: Basic Ideas and Selected Topics. New York: Olden-Day; 1977.
70. Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am. 2000;14(4):925-38. (Pubitemid 30636694)
71. Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one- time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95(7):1800-11. (Pubitemid 30485022)
72. Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer. 2004;111(4): 633-9. (Pubitemid 39045333)
73. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156(8):761-73. (Pubitemid 35155183)
74. Chia YL, Salzman P, Plevritis SK, Glynn PW. Simulationn- based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res. 2004;13(6):507-24. (Pubitemid 39562705)
75. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007;166(2):137-50. (Pubitemid 47227293)
76. Press BP, Teukolsky SA, Vetterby WT, Flannery BP. Numerous Recipes in Fortran-The Art of Scientific Computing. New York: Cambridge University Press; 1992.
77. Tan SY, van Oortmarrsen GJ. Estimating parameters of a microsimulation model for breast cancer screening using the score function method. Annals of Operations Research. 2003;119: 43-61.
78. Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. J Am Stat Assoc. 1998;93:1271-81. (Pubitemid 128385542)
79. Shen Y, Zelen M. Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding. Biometrika. 1999;86(3):503-15. (Pubitemid 129766055)
80. Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics. 2005;6(4):604-14. (Pubitemid 41442773)
81. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006;25(16):2846-66. (Pubitemid 44193388)
82. Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics. 1987;43(1): 127-44. (Pubitemid 17063898)
83. Parmigiani G. Measuring uncertainty in complex decision analysis models. Stat Methods Med Res. 2002;11(6):513-37. (Pubitemid 36096868)
84. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006(36):30-6.
85. Rutter CM, Miglioretti DL, Savarino JE. Bayesian calibration of microsimulation models. J Am Stat Assoc. 2009;104(488):1338-50.
86. Craig BA, Fryback DG, Klein R, Klein BE. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. Stat Med. 1999;18(11):1355-71. (Pubitemid 29261494)
87. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
88. Dewilde S, Anderson R. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Med Decis Making. 2004;24(5):486-92. (Pubitemid 39223701)
89. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92. (Pubitemid 41549890)
90. Cronin KA, Legler JM, Etzioni RD. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Stat Med. 1998;17(21):2509-23. (Pubitemid 28488403)
91. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5(2):157-77. (Pubitemid 16130640)
92. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 1986; 6(2):85-92. (Pubitemid 16121227)
93. Griffin S, Claxton K, Hawkins N, Sculpher M. Probabilistic analysis and computationally expensive models: necessary and required? Value Health. 2006;9(4):244-52. (Pubitemid 44126779)
94. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354(9173):99-105. (Pubitemid 29313143)
95. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist. 2001;6(2):147-52. (Pubitemid 32323453)
96. Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003;124(2):614-21. (Pubitemid 37000142)
97. Marshall D, Simpson KN, Earle CC, Chu CW. Economic decision analysis model of screening for lung cancer. Eur J Cancer. 2001;37(14):1759-67. (Pubitemid 32817050)
98. Chirikos TN, Hazelton T, Tockman M, Clark R. Screening for lung cancer with CT. Chest. 2002;121:1507-14.
99. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003;289(3):313-22. (Pubitemid 36083984)
100. Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. Journal of the Royal Statistical Society, Series A: Statistics in Society. 2009;172:282-404.
101. Parmigiani G, Ancukiewicz M, Matchar DB. Decision models in clinical recommendations development: the Stroke Prevention Policy Model. In: Berry DA, Stangl DK, eds. Bayesian Biostatistics. Vol 151. New York: Marcel Dekker; 1996. p 207-33.
102. Thurston SW, Zaslavsky AM. Variance estimation in microsimulation models of the Food Stamp Program, 1996 Proceedings of the Social Statistics Section, American Statistical Association, pp 4-9, August 4-8, Chicago, IL.
103. Zaslavsky AM, Thurston SW. Error analysis of food stamp microsimulation models: Further results, 1995 Proceedings of the Social Statistics Section, American Statistical Association, pp 151-156, August 13-17, Orlando, FL.
104. Eddy DM. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics. 2006;24(9):837-44. (Pubitemid 44338295)
105. Fendrick AM. The future of health economic modeling: have we gone too far or not far enough? Value Health. 2006;9(3): 179-80.
106. CISNET. 2009. Available from: http://cisnet.cancer.gov. Accessed June 12, 2009.
107. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices- Modeling Studies. Value Health. 2003;6(1):9-17. (Pubitemid 36228345)
108. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complication. Diabetes Care. 2004;27(9):2262-5.
109. Statistics Canada. 2009. Available from: http://www.statcan.gc.ca/start- debut-eng.html Accessed June 12, 2009.
110. International Microsimulation Association. 2009. Available from: www.microsimulation.org. Accessed June 12, 2009.